📰 Cybin Corp News
Cybin Corp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cybin Corp. Real-time updates on events, politics, business and more.
April 18, 2024
Marketresearch.biz reports that Psychedelic Drugs Market size is expected to be worth around USD 5.1 Bn by 2032 from USD 2.5 Bn in 2022, growing at a CAGR of 7.6% during the forecast period from 2023 to 2032.Overview of the Psychedelic Drugs MarketThe Psychedelic Drugs Market is experiencing a renaissance, driven by...
February 1, 2024
/PRNewswire/ -- The "Global Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.coms offering....
September 14, 2023
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR ...
August 28, 2023
Data Bridge Market research has recently released expansive research titled Global Psychedelic Drugs Market guarantees you will remain better informed than your competition. This study provides the broader perspective of the market place with its comprehensive market insights and analysis which eases surviving and s...
August 18, 2023
CYBIN INC. STATEMENT OF EXECUTIVE COMPENSATION For the financial year ended March 31, 2023 This statement of executive compensation for Cybin...
August 14, 2023
CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022 ... -Today at 07:43 am- MarketScreener
April 27, 2023
/PRNewswire/ -- The "Psychedelic Drugs: Global Market Outlook" report has been added to ResearchAndMarkets.coms offering. The global market for psychedelic...
April 27, 2023
Dublin, April 27, 2023 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering. ...
November 21, 2022
Europe Psychedelic Drugs Market report is a definitive solution for sound decision making and superior management of goods and services. This market research report endows clients with the supreme level of market data and information which exactly matches to the niche and business requirements. This Europe Psychedel...
June 4, 2022
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the milestones identifi...